Wikipedia -WSS

Wikipedia

author：entertainment 2025-10-01 02:13:22 - browse：353

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice?

Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them. The medicines, after all, are pricey, come with side effects, and won’t work for everyone. And despite the excitement around these drugs, known as GLP-1s, some people might prefer or see better results with the other approaches that have long been the foundation of obesity treatment, from diet to surgery.

“These drugs clearly are very effective, and that is fantastic,” said Susan Jebb, a professor of diet and population health at the University of Oxford and one of the leaders of the project. “But we have other options for treating obesity. What we need to do now in research is understand which treatments, for which patients, at which stage of their disease.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The lessons of Aduhelm, an Alzheimer's drug that was not to be

WSS

SAMSHA loosens regulations on methadone treatment centers

Healthy food access boosts outcomes in two studies

Carbon Health diabetes program, a test of data

Ohio still needs to do more to protect the right to abortion

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Cancer diagnosis changes perspective doctor, former hospital CEO

explore

Wikipedia

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

A $475,000 price tag for a new cancer drug: crazy or meh?

The cancer drug shortage isn’t new — and neither are the solutions

Medicare drug price negotiation’s day in court

In age of alternative facts, a scholarly course on calling out crap

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Psychedelics group wrestles with new pharma identity

Do digital therapeutics have a future in medicine?

Walensky prepares to leave CDC — and Congress — behind

Cybersecurity threat forces Lurie Children's to take systems offline

explore

What we need to know about Arena Bioworks

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Do digital therapeutics have a future in medicine?

Cognito secures funding to test medical device for Alzheimer's

Ventyx halts psoriasis drug development after lackluster trial results

Readout Newsletter: Zepbound, Valneva's vaccine, and more

focus

leisure time

leisure time

knowledge